Thursday, June 23, 2016 3:26:28 PM
June 23, 2016 by Gary Culliton
Click For Article
The effectiveness and tolerability of buprenorphine for treating cancer pain was discussed at the World Research Congress of the European Association of Palliative Care meeting in Dublin by Dr Mark Taubert, Consultant in Palliative Medicine and Clinical Lead for Palliative Care, Velindre Cancer Centre in Wales.
Dr Taubert discussed a Cochrane review (Schmidt-Hansen), on which he was a co-author, which assessed the effectiveness and tolerability of buprenorphine for cancer pain in adults and children.
For example, a person might present, having started on a buprenorphine transdermal patch, Dr Taubert said.
Buprenorphine is less constipating than morphine, studies have found (Bach 1991, Robbie 1979, PACE 2007). Buprenorphine had a long duration of action and it took time to leave the system, Dr Taubert said.
Cancer background pain was considered and — as in a number of previous Cochrane reviews — pain intensity was one primary outcome. Secondary outcomes included adverse effects. A total of 19 studies, published across 23 articles were considered, which had enrolled 1,421 patients.
In studies that considered transdermal buprenorphine, a clear dose–response relationship was not shown.
When transdermal buprenorphine was compared to controlled release morphine (PACE 2007), buprenorphine was associated with significantly lower pain scores.
Morphine patients had significantly higher rates of vertigo, constipation and nausea. However, there was no difference between the groups in terms of drowsiness, headaches and confusion.
Intramuscular bupren-orphine was found to have a similar analgesic effect compared to intramuscular morphine (Rigolot 1979).
Another study also showed similar maximum pain intensity outcomes, but buprenorphine side-effects (dizziness, nausea) were encountered (Kjaer 1982).
Transdermal buprenorphine and transdermal fentanyl showed similar outcomes (Sarhan 2009) in terms of mean pain scores, added Dr Taubert.
Blessings to All
TRUTH
I've never claimed to have all the answers but feel i'm beginning to corner the market in questions worthy of them.
Recent TTNP News
- Form 8-K - Current report • Edgar (US Regulatory) • 01/25/2024 09:33:11 PM
- Titan Pharmaceuticals Fully Compliant With NASDAQ Listing Criteria • GlobeNewswire Inc. • 01/25/2024 09:29:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/18/2024 09:59:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 10:13:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:30:20 PM
- Titan Pharmaceuticals Announces Reverse Stock Split and Ratio • GlobeNewswire Inc. • 12/28/2023 09:15:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2023 09:47:46 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/17/2023 09:03:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/15/2023 09:05:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/26/2023 08:33:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/26/2023 08:31:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/26/2023 08:29:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/26/2023 08:25:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/26/2023 08:23:37 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 10/24/2023 09:26:34 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 10/23/2023 07:07:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/16/2023 09:08:35 PM
- Titan Pharmaceuticals Announces Appointment of Dato' Seow Gim Shen and Brynner Chaim to the Company's Board of Directors • GlobeNewswire Inc. • 10/16/2023 08:37:23 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 10/04/2023 09:30:18 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 09/19/2023 08:41:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2023 08:45:22 PM
- Titan Pharmaceuticals Announces $9.5 Million Private Placement of Convertible Preferred Stock • GlobeNewswire Inc. • 09/18/2023 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/08/2023 09:30:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/30/2023 08:28:25 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM